These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 36573005)
21. Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults - United States, December 2020-March 2023. Montoy JCC; Ford J; Yu H; Gottlieb M; Morse D; Santangelo M; O'Laughlin KN; Schaeffer K; Logan P; Rising K; Hill MJ; Wisk LE; Salah W; Idris AH; Huebinger RM; Spatz ES; Rodriguez RM; Klabbers RE; Gatling K; Wang RC; Elmore JG; McDonald SA; Stephens KA; Weinstein RA; Venkatesh AK; Saydah S; MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(32):859-865. PubMed ID: 37561663 [TBL] [Abstract][Full Text] [Related]
22. Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID). Pazukhina E; Rumyantsev M; Baimukhambetova D; Bondarenko E; Markina N; El-Taravi Y; Petrova P; Ezhova A; Andreeva M; Iakovleva E; Bobkova P; Pikuza M; Trefilova A; Abdeeva E; Galiautdinova A; Filippova Y; Bairashevskaia A; Zolotarev A; Bulanov N; DunnGalvin A; Chernyavskaya A; Kondrikova E; Kolotilina A; Gadetskaya S; Ivanova YV; Turina I; Eremeeva A; Fedorova LA; Comberiati P; Peroni DG; Nekliudov N; Genuneit J; Reyes LF; Brackel CLH; Mazankova L; Miroshina A; Samitova E; Borzakova S; Carson G; Sigfrid L; Scott JT; McFarland S; Greenhawt M; Buonsenso D; Semple MG; Warner JO; Olliaro P; Osmanov IM; Korsunskiy AA; Munblit D; BMC Med; 2024 Feb; 22(1):48. PubMed ID: 38302974 [TBL] [Abstract][Full Text] [Related]
23. Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection. Richard SA; Pollett SD; Fries AC; Berjohn CM; Maves RC; Lalani T; Smith AG; Mody RM; Ganesan A; Colombo RE; Lindholm DA; Morris MJ; Huprikar N; Colombo CJ; Madar C; Jones M; Larson DT; Bazan SE; Mende K; Saunders D; Livezey J; Lanteri CA; Scher AI; Byrne C; Rusiecki J; Ewers E; Epsi NJ; Rozman JS; English C; Simons MP; Tribble DR; Agan BK; Burgess TH; JAMA Netw Open; 2023 Jan; 6(1):e2251360. PubMed ID: 36652247 [TBL] [Abstract][Full Text] [Related]
24. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. Khan M; Khan H; Khan S; Nawaz M J Med Microbiol; 2020 Aug; 69(8):1114-1123. PubMed ID: 32783802 [No Abstract] [Full Text] [Related]
26. Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study. Adler L; Gazit S; Pinto Y; Perez G; Mizrahi Reuveni M; Yehoshua I; Hoffman R; Azuri J; Patalon T Scand J Prim Health Care; 2022 Sep; 40(3):342-349. PubMed ID: 36314555 [TBL] [Abstract][Full Text] [Related]
27. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
29. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289 [TBL] [Abstract][Full Text] [Related]
30. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Stephenson T; Pinto Pereira SM; Shafran R; de Stavola BL; Rojas N; McOwat K; Simmons R; Zavala M; O'Mahoney L; Chalder T; Crawley E; Ford TJ; Harnden A; Heyman I; Swann O; Whittaker E; ; Ladhani SN Lancet Child Adolesc Health; 2022 Apr; 6(4):230-239. PubMed ID: 35143770 [TBL] [Abstract][Full Text] [Related]
31. Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group. Cazé AB; Cerqueira-Silva T; Bomfim AP; de Souza GL; Azevedo AC; Brasil MQ; Santos NR; Khouri R; Dan J; Bandeira AC; Cavalcanti LP; Barral-Netto M; Barral A; Barbosa CG; Boaventura VS J Glob Health; 2023 May; 13():06015. PubMed ID: 37166260 [TBL] [Abstract][Full Text] [Related]
32. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197 [TBL] [Abstract][Full Text] [Related]
33. The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study. Fernández-de-Las-Peñas C; Gómez-Mayordomo V; Cuadrado ML; Palacios-Ceña D; Florencio LL; Guerrero AL; García-Azorín D; Hernández-Barrera V; Arendt-Nielsen L Cephalalgia; 2021 Nov; 41(13):1332-1341. PubMed ID: 34134526 [TBL] [Abstract][Full Text] [Related]
34. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Huang C; Huang L; Wang Y; Li X; Ren L; Gu X; Kang L; Guo L; Liu M; Zhou X; Luo J; Huang Z; Tu S; Zhao Y; Chen L; Xu D; Li Y; Li C; Peng L; Li Y; Xie W; Cui D; Shang L; Fan G; Xu J; Wang G; Wang Y; Zhong J; Wang C; Wang J; Zhang D; Cao B Lancet; 2021 Jan; 397(10270):220-232. PubMed ID: 33428867 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Alkodaymi MS; Omrani OA; Fawzy NA; Shaar BA; Almamlouk R; Riaz M; Obeidat M; Obeidat Y; Gerberi D; Taha RM; Kashour Z; Kashour T; Berbari EF; Alkattan K; Tleyjeh IM Clin Microbiol Infect; 2022 May; 28(5):657-666. PubMed ID: 35124265 [TBL] [Abstract][Full Text] [Related]
37. Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection. Shenoy ES; Wickner PG; West LR; Banerji A; Blumenthal KG; Centi AJ; Gottlieb A; Hashimoto DM; Kim E; Kim M; Lee H; Simpson LA; Landman AB Infect Control Hosp Epidemiol; 2022 Oct; 43(10):1439-1446. PubMed ID: 34726142 [TBL] [Abstract][Full Text] [Related]
38. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735 [TBL] [Abstract][Full Text] [Related]
39. Long COVID in a highly vaccinated but largely unexposed Australian population following the 2022 SARS-CoV-2 Omicron wave: a cross-sectional survey. Woldegiorgis M; Cadby G; Ngeh S; Korda RJ; Armstrong PK; Maticevic J; Knight P; Jardine A; Bloomfield LE; Effler PV Med J Aust; 2024 Apr; 220(6):323-330. PubMed ID: 38508863 [TBL] [Abstract][Full Text] [Related]
40. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Peghin M; Palese A; Venturini M; De Martino M; Gerussi V; Graziano E; Bontempo G; Marrella F; Tommasini A; Fabris M; Curcio F; Isola M; Tascini C Clin Microbiol Infect; 2021 Oct; 27(10):1507-1513. PubMed ID: 34111579 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]